retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Full data just presented at the ADA conference to a packed room. Just a refresher, it is a GLP-1/GIP/Glucagon agonist. It hits all three receptors as opposed to semaglutide which hits Retatrutide—A Game Changer in Obesity
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
























